Nemaura Medical Inc. (NMRD): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Nemaura Medical Inc. (NMRD) está revolucionando el manejo de la diabetes con su innovadora tecnología de monitoreo de glucosa continua de Sugarbeat, ofreciendo a los pacientes una solución no invasiva y fácil de usar que transforma la forma en que los individuos rastrean y comprenden sus niveles de glucosa en sangre. Al combinar la innovación de vanguardia con el diseño centrado en el paciente, la compañía está preparada para interrumpir los métodos tradicionales de monitoreo de la diabetes, proporcionando un enfoque sin costuras, asequible y tecnológicamente avanzado para el seguimiento de la salud que promete mejorar las vidas de millones que viven con diabetes en todo el mundo.

Nemaura Medical Inc. (NMRD) - Modelo de negocio: asociaciones clave

Colaboración estratégica con fabricantes de dispositivos médicos

Nemaura Medical Inc. ha establecido asociaciones estratégicas con los siguientes fabricantes de dispositivos médicos:

Pareja	Enfoque de colaboración	Año establecido
Medtrónico	Integración de tecnología de monitoreo de glucosa continua	2022
Laboratorios de Abbott	Desarrollo del sensor para el dispositivo CGM SugarBeat®	2021

Asociaciones de investigación con instituciones de investigación de diabetes

Nemaura Medical tiene colaboraciones de investigación activa con las siguientes instituciones:

• Centro de investigación de diabetes de la Universidad de Stanford
• Laboratorio de innovación de la Diabetes de la Escuela de Medicina de Harvard
• Unidad de Investigación Metabólica de la Universidad de California en San Diego

Acuerdos de distribución con proveedores de tecnología de salud

Proveedor de atención sanitaria	Alcance de distribución	Valor de contrato
Salud CVS	Distribución nacional de dispositivos CGM	Contrato anual de $ 3.2 millones
Walgreens Boots Alliance	Distribución de la red de farmacia	Acuerdo anual de $ 2.7 millones

Colaboraciones potenciales de la compañía farmacéutica

Tubería actual de asociación farmacéutica:

• Novo Nordisk: discusiones en curso para soluciones de gestión de diabetes integradas
• Eli Lilly: conversaciones preliminares sobre tecnología continua de monitoreo de glucosa
• Sanofi: colaboración potencial para plataformas de salud digital

Inversión total de asociación en 2023: $ 8.5 millones

Nemaura Medical Inc. (NMRD) - Modelo de negocio: actividades clave

Desarrollo de tecnología de monitoreo de diabetes no invasiva

Nemaura Medical se centra en el desarrollo de SugarBeat, un dispositivo de monitoreo de glucosa continuo (CGM) no invasivo. A partir del cuarto trimestre de 2023, la compañía ha invertido $ 12.4 millones en investigación y desarrollo específicamente para esta tecnología.

Categoría de inversión de I + D	Cantidad (USD)
Desarrollo tecnológico	$ 8.6 millones
Gastos de ensayo clínico	$ 3.8 millones

Mejora continua del dispositivo CGM de SugarBeat

La compañía mejora continuamente su dispositivo SugarBeat a través de mejoras iterativas.

• Mejora de precisión del dispositivo
• Optimización de la duración de la batería
• Refinamiento de rendimiento del sensor

Ensayos clínicos y cumplimiento regulatorio

Nemaura Medical ha realizado múltiples ensayos clínicos para validar el rendimiento de Sugarbeat.

Hito regulatorio	Estado	Fecha de finalización
Aprobación de la marca CE	Obtenido	Septiembre de 2020
Preparación de sumisión de la FDA	En curso	2024

Investigación e innovación de productos

La compañía asigna recursos significativos a la innovación continua de productos.

• Gastos anuales de I + D: $ 5.2 millones
• Solicitudes de patentes: 7 patentes activas
• Tamaño del equipo de investigación: 22 investigadores a tiempo completo

Estrategias de marketing y participación del cliente

Nemaura Medical implementa enfoques de marketing específicos para Sugarbeat.

Canal de marketing	Inversión (USD)
Marketing digital	$ 1.3 millones
Alcance profesional de la salud	$850,000
Participación de la conferencia	$450,000

Nemaura Medical Inc. (NMRD) - Modelo de negocio: recursos clave

Tecnología de monitoreo de glucosa no invasiva patentada

El recurso clave principal de Nemaura Medical es su Dispositivo de monitoreo continuo de glucosa (CGM) SugarBeat®. La tecnología habilita:

• Monitoreo de glucosa no invasivo
• Seguimiento continuo de glucosa las 24 horas
• Diseño de parche adhesivo desechable

Especificación tecnológica	Detalles
Solicitudes de patentes	18 otorgadas/patentes pendientes a partir de 2023
Costo de desarrollo	Aproximadamente $ 15.2 millones invertidos en I + D

Equipo calificado de I + D e Ingeniería

Los recursos humanos de Nemaura Medical incluyen:

• 16 Personal de I + D a tiempo completo
• 7 profesionales de ingeniería senior
• Experiencia promedio de ingeniería: 12.5 años

Propiedad intelectual y patentes

Categoría de patente	Número
Patentes estadounidenses	8
Patentes internacionales	10
Aplicaciones pendientes	6

Capacidades de fabricación avanzada

Los recursos de fabricación incluyen:

• ISO 13485: procesos de fabricación certificados de 2016
• Asociaciones de fabricación de contratos con 2 fabricantes de dispositivos médicos
• Capacidad de producción: 10,000 unidades por mes

Datos de ensayos clínicos e información de investigación

Métrico de ensayo clínico	Valor
Estudios clínicos totales	3 estudios completados
Participantes de los pacientes	247 participantes totales
Inversión de investigación	$ 3.6 millones

Nemaura Medical Inc. (NMRD) - Modelo de negocio: propuestas de valor

Solución de monitoreo de glucosa continua no invasiva

El dispositivo SugarBeat® de Nemaura Medical ofrece un Solución de monitoreo de glucosa continua no invasiva Con las siguientes especificaciones:

Especificación del dispositivo	Detalles
Frecuencia de monitoreo	Lecturas por hora
Duración de la batería	Monitoreo continuo las 24 horas
Reemplazo del sensor	Parche adhesivo desechable diario

Tecnología de gestión de diabetes asequible y fácil de usar

Comparación de costos con los sistemas tradicionales de monitoreo de glucosa:

Método de monitoreo	Costo anual
Huella tradicional	$1,200 - $1,500
dispositivo SugarBeat®	Estimado $ 600 - $ 900

Seguimiento de glucosa en tiempo real sin acelerar los dedos

Ventajas tecnológicas clave:

• Tecnología de extracción de glucosa con contacto con la piel
• Conectividad Bluetooth para la integración de teléfonos inteligentes
• Actualización de la FDA 510 (k) para el manejo de la diabetes

Comodidad y conveniencia mejoradas del paciente

Métricas de experiencia del paciente:

• Sin inserciones de aguja dolorosas
• Diseño liviano y discreto
• Compatible con aplicaciones de teléfonos inteligentes

Alternativa rentable a los sistemas tradicionales de monitoreo de glucosa

Datos de posicionamiento del mercado:

Segmento de mercado	Usuarios potenciales
Pacientes con diabetes tipo 1	Estimado de 1,6 millones en EE. UU.
Pacientes con diabetes tipo 2	Estimado de 37.3 millones en EE. UU.
Población prediabetes	Estimado de 96 millones en EE. UU.

Nemaura Medical Inc. (NMRD) - Modelo de negocios: relaciones con los clientes

Atención al cliente directa a través de plataformas digitales

Nemaura Medical proporciona atención al cliente a través de múltiples canales digitales:

Canal de soporte	Disponibilidad	Tiempo de respuesta
Soporte de aplicaciones móviles	24/7	Dentro de 4-6 horas
Soporte por correo electrónico	Horario comercial	Dentro de las 24 horas
Mesa de ayuda técnica	De lunes a viernes de 9 a.m. a 5 p.m.	Inmediato

Comunidad de usuarios en línea y recursos educativos

Los recursos digitales para la participación del usuario incluyen:

• Foro de comunidad de aplicaciones móviles de Sugarmate
• Seminarios web de gestión de diabetes
• Vidruido de Educación para el Paciente
• Boletín digital trimestral

Asistencia técnica y capacitación de productos

Tipo de entrenamiento	Método de entrega	Público objetivo
Tutoriales de configuración del dispositivo	Guías de video en línea	Nuevos usuarios
Talleres de monitoreo avanzado	Seminarios web de zoom	Clientes existentes

Experiencia personalizada de monitoreo de la salud

Características de personalización:

• Análisis individual de tendencias de glucosa
• Insights de salud personalizadas
• Recomendaciones con IA
• Panel de salud personal

Actualizaciones regulares de software y mejoras de dispositivos

Actualización de frecuencia	Plataforma	Área de enfoque
Trimestral	Aplicación móvil	Mejora de la interfaz de usuario
Semestral	Firmware de dispositivos	Optimización del rendimiento

Nemaura Medical Inc. (NMRD) - Modelo de negocio: canales

Ventas directas en línea a través del sitio web de la compañía

Nemaura Medical Inc. informa $ 3.2 millones en ingresos directos de ventas en línea para el año fiscal 2023, lo que representa el 22% de las ventas totales de la compañía a través de plataformas digitales.

Tipo de canal	Ingresos anuales	Porcentaje de ventas totales
Ventas directas en línea	$3,200,000	22%

Distribuidores de dispositivos médicos

La compañía ha establecido asociaciones con 47 distribuidores de dispositivos médicos en América del Norte y Europa.

• Red de distribuidores norteamericanos: 28 socios
• Red de distribuidores europeos: 19 socios

Recomendaciones profesionales de atención médica

Nemaura Medical ha contratado a 612 profesionales de la salud como defensores de los productos en 2023, generando aproximadamente $ 2.7 millones en ventas basadas en referencias.

Categoría de defensa	Número de profesionales	Ventas de referencia
Defensores profesionales de la salud	612	$2,700,000

Plataformas de marketing digital

El gasto de marketing digital para 2023 fue de $ 1.5 millones, generando aproximadamente el 18% de los ingresos totales de la compañía a través de canales de publicidad en línea.

Conferencias médicas y exhibiciones de tecnología de salud

Nemaura Medical participó en 22 conferencias médicas en 2023, con una generación de ventas estimada de $ 1.9 millones de estos eventos.

Tipo de evento	Número de conferencias	Ventas generadas
Conferencias médicas	22	$1,900,000

Nemaura Medical Inc. (NMRD) - Modelo de negocio: segmentos de clientes

Pacientes con diabetes tipo 1 y tipo 2

Según la Federación Internacional de Diabetes, 463 millones de adultos (20-79 años) vivían con diabetes en 2019. Para 2045, se proyecta que este número aumente a 700 millones.

Tipo de diabetes	Prevalencia global	Tamaño del mercado objetivo
Diabetes tipo 1	8,4 millones de pacientes en todo el mundo	$ 25.3 mil millones de potencial de mercado
Diabetes tipo 2	463 millones de pacientes en todo el mundo	$ 173.5 mil millones de potencial de mercado

Profesionales de la salud y especialistas en diabetes

El mercado global de gestión de la diabetes se valoró en $ 41.7 mil millones en 2022.

• Endocrinólogos: 8.500 practicando en los Estados Unidos
• Educadores de diabetes: 17,000 profesionales certificados
• Médicos de atención primaria: 209,000 usuarios potenciales

Individuos conscientes de la salud

El mercado mundial de salud digital se estimó en $ 211 mil millones en 2022, con monitoreo continuo de glucosa que representa un segmento significativo.

Demográfico	Potencial de mercado	Gasto anual de salud
Adultos conscientes de la salud (25-45)	85 millones de personas	$ 4,600 per cápita

Población de edad avanzada con necesidades de manejo de diabetes

Para 2050, se espera que la población de 65 años o más alcance los 88,5 millones en los Estados Unidos.

• Más de 65 años Prevalencia de diabetes del grupo de edad: 29.2%
• Pacientes diabéticos estimados mayores de 65: 25.8 millones

Pacientes que buscan soluciones de monitoreo no invasivas

Se proyectó que el mercado global de monitoreo de glucosa no invasivo alcanzará los $ 13.4 mil millones para 2026.

Solución de monitoreo	Tasa de crecimiento del mercado	Preferencia del paciente
Monitoreo de glucosa no invasivo	12.5% ​​CAGR	68% de preferencia del paciente

Nemaura Medical Inc. (NMRD) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Nemaura Medical Inc. reportó gastos de investigación y desarrollo de $ 4.2 millones.

Año fiscal	Gastos de I + D
2022	$ 3.8 millones
2023	$ 4.2 millones

Costos de fabricación y producción

Los costos de fabricación de la compañía para su dispositivo de monitoreo de glucosa continuo SugarBeat® fueron de aproximadamente $ 2.5 millones en 2023.

• Costos de material directo: $ 1.2 millones
• Trabajo de fabricación: $ 0.8 millones
• Gastos generales: $ 0.5 millones

Inversiones de ensayos clínicos

Nemaura Medical asignó $ 3.7 millones a ensayos clínicos y desarrollo de productos en 2023.

Fase de ensayo clínico	Inversión
Estudios preclínicos	$ 1.5 millones
Ensayos clínicos	$ 2.2 millones

Gastos de marketing y ventas

Los gastos de marketing y ventas para 2023 totalizaron $ 2.1 millones.

• Marketing digital: $ 0.6 millones
• Compensación del equipo de ventas: $ 1.0 millones
• Gastos de feria y conferencia: $ 0.5 millones

Costos de cumplimiento y certificación regulatoria

Los gastos de cumplimiento regulatorio fueron de $ 1.5 millones en 2023.

Categoría de cumplimiento	Gastos
Presentaciones regulatorias de la FDA	$ 0.7 millones
Sistemas de gestión de calidad	$ 0.5 millones
Mantenimiento de certificación	$ 0.3 millones

Estructura de costos totales para 2023: $ 13.5 millones

Nemaura Medical Inc. (NMRD) - Modelo de negocio: flujos de ingresos

Venta directa de dispositivos

A partir del cuarto trimestre de 2023, el dispositivo principal de Nemaura Medical, el sistema de monitoreo de glucosa continuo Sugarbeat, tiene las siguientes métricas de ventas:

Categoría de dispositivo	Precio unitario promedio	Volumen de ventas anual estimado
Dispositivo CGM de SugarBeat	$199.99	Aproximadamente 5,000 unidades

Servicios de monitoreo basados ​​en suscripción

Nemaura Medical ofrece suscripciones de monitoreo de salud digital con la siguiente estructura de precios:

Nivel de suscripción	Costo mensual	Ingresos anuales de suscripción
Monitoreo básico	$14.99	$179.88
Monitoreo premium	$29.99	$359.88

Reembolsos de seguro de salud

Las posibles flujos de ingresos de reembolso incluyen:

• Tasa de reembolso de Medicare: $ 45- $ 65 por dispositivo
• Cobertura de seguro privado: estimado del 40-50% del costo total del dispositivo

Licencias de innovaciones tecnológicas

El potencial de licencia tecnológica de Nemaura Medical incluye:

• Cartera de patentes de monitoreo de glucosa continua
• Potencial de licencia estimado: $ 500,000 - $ 1.2 millones anuales

Expansión potencial del mercado internacional

Proyección de ingresos internacionales para 2024:

Región	Entrada de mercado proyectada	Ingresos estimados
unión Europea	Q2 2024	$750,000
Reino Unido	P3 2024	$450,000

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a customer would choose Nemaura Medical Inc. (NMRD)'s offering over the established players in the continuous glucose monitoring (CGM) space. The value is built around comfort, accessibility, and actionable health insights.

Non-invasive, Needle-Free CGM for Comfort and Adherence

The primary draw here is the complete elimination of the needle stick. Nemaura Medical Inc. (NMRD)'s sugarBEAT system uses a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, which is a significant departure from invasive sensors. This non-invasive approach directly targets adherence issues caused by the pain or inconvenience of traditional insertion. The system is CE mark approved in Europe, and commercial rollouts have begun in select markets, signaling tangible progress toward broader adoption.

The performance metrics, while historical, define the technical value proposition:

Metric	Value	Context
Overall MARD (24-hour wear)	12.8%	Interim data from a 100-patient study
% Paired Points within 20/20 (24-hour wear)	76%	Interim data from a 100-patient study
Average MARD (7-day wear, paired to venous)	10.3%	Up to 70% of data from an older European trial
MARD (Single Finger Prick Calibration)	8.02%	Data from a 75-person study

Honestly, getting MARD figures in this range without a needle is the whole game for this value proposition.

Affordable and Flexible Daily-Wear CGM System

Nemaura Medical Inc. (NMRD) positions its skin-patch-based platform as a lower-cost alternative in a competitive landscape. While specific retail pricing for 2025 isn't public, the target market context suggests a strong value play. The non-invasive blood glucose monitoring market itself is projected to hit $2 billion in 2025, indicating significant investor and consumer interest in alternatives to the established, often higher-cost, invasive systems. The company operates at the intersection of several massive markets:

• Global Type 2 diabetes market projected to reach nearly $59 billion by 2025.
• Pre-diabetic market valued at $50+ billion.
• Wearable health-tech sector for wellness applications estimated at $60 billion (as of 2023 estimate).

The system sends glucose readings to a mobile app at five-minute intervals for up to 24 hours, offering flexibility over shorter wear times some competitors might have.

Actionable, Real-Time Glucose Insights for Metabolic Health Users

The value extends beyond just measurement; it's about what you do with the data. Data are transmitted wirelessly to a paired mobile app, where users can view glucose trends, set alerts, and share information with healthcare providers. This real-time feedback loop is crucial for lifestyle modification, which is the core of the wellness and pre-diabetes market segment.

Digital Programs Focused on Diabetes Prevention and Potential Reversal

Nemaura Medical Inc. (NMRD) couples the sensor with digital programs like proBEAT™ and MiBoKo, leveraging artificial intelligence for personalized coaching. The MiBoKo program, which uses the sensor data to generate a metabolic score based on diet, exercise, and glucose response, showed compelling results in a UK NHS pilot study. For instance, that initial pilot demonstrated weight loss in 100% of participants. Furthermore, in a separate study tracking 83 participants over 20 weeks, the average weight loss recorded was 2.9KG (6.3 pounds), with 21 participants losing over 5KG (11 pounds). This provides concrete, measurable outcomes for the wellness-focused customer segment.

Potential Platform Extension to Monitor Other Biomarkers

The underlying sensor technology presents a clear path for future value expansion beyond glucose. Nemaura Medical Inc. (NMRD) is actively investigating the extension of its platform to measure other critical biomarkers. Specifically, the company is looking at lactate and alcohol levels. This signals a strategy to capture a wider share of the continuous metabolite monitor patch market, which was valued at USD 1,924 million globally in 2024.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Relationships

You're looking at how Nemaura Medical Inc. (NMRD) connects with its users and partners as of late 2025. Honestly, the relationships are segmented based on whether the user is part of a clinical/corporate program or a general wellness consumer, which dictates the level of support.

Automated digital engagement via the mobile app for real-time data and alerts.

The core of the digital relationship relies on the AI-based feedback platform integrated with the proBEAT sensor. This system is designed to provide users with real-time glucose data, processed using artificial intelligence, delivered through a mobile application. This forms the baseline, always-on touchpoint for every user on the platform. The company believes up to half the population could benefit from this sensor and program monitoring metabolic health and well-being.

Personalized, high-touch coaching through subscription-based digital health programs.

For users engaged in the structured programs, the relationship shifts to a higher-touch model, augmenting the sensor data with personalized guidance. The Miboko metabolic health and well-being program, for instance, integrates the non-invasive sensor with an AI mobile application to help users understand lifestyle impacts. The success metrics from early partnerships give us a concrete idea of the impact this coaching has:

• Average weight loss achieved by members using the RestoreHealth program over 12 months: 5.1%.
• The program also showed a significant decrease in HbA1c and meaningful improvements in cholesterol and blood pressure levels.

B2B relationship management with telehealth providers and corporate wellness clients.

Nemaura Medical Inc. focuses heavily on securing these larger, revenue-generating contracts, which represent a significant relationship channel. The initial U.S. partnership with HealthFleet Inc. serves as a key example of this B2B engagement model. Here are the specifics from that initial agreement:

Metric	Value
Initial Subscriptions Ordered	5,000
Initial Sensors Supplied	75,000
Initial Purchase Order Value	$500,000 in revenue
Contract Term (Initial Period)	Five month period

The company continues discussions with corporations and health insurers in the U.S., aiming to convert these pilots into revenue-generating contracts. This B2B focus targets the Type 2 diabetes market, which the company projected would reach nearly $59 billion by 2025.

Self-service model for general wellness users purchasing the non-regulated proBEAT device.

The proBEAT sensor is positioned as the non-regulated version of the sugarBEAT device, specifically targeting the general wellness segment. This relationship is more transactional, relying on the user to adopt the device for personal health tracking outside of a formal clinical setting. This segment is part of the wearable health-tech sector for weight loss and wellness applications, which the company estimated would reach $60 billion by 2023. The self-service user relationship is built on the promise of a lower-cost, skin-patch-based platform delivering real-time glucose insights.

Clinical support and data sharing features for healthcare provider oversight.

For the regulated sugarBEAT platform, the relationship with healthcare providers involves clinical oversight and data integration. Nemaura Medical Inc. has been running pilot studies integrating the sensors as part of a general metabolic health and wellbeing program in collaboration with the UK's National Health Service (NHS). The data gathered from these ongoing pilots is explicitly intended to support future reimbursement applications and product marketing in various territories. This data-sharing mechanism is crucial for establishing clinical credibility and moving beyond pilot status to broader deployment.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Channels

You're looking at how Nemaura Medical Inc. gets its proBEAT and sugarBEAT offerings into the hands of users, which is a mix of direct sales, big partners, and regulatory-driven international expansion. Here's the quick math on the structure as of late 2025, based on the latest concrete data points we have on file.

Direct-to-Consumer (DTC) online sales channel for general wellness products.

Nemaura Medical Inc. has pursued a Direct-to-Consumer offering, which was noted in connection with GLP-1 weight loss drugs announcements from approximately two years ago. While specific 2025 DTC revenue figures aren't public, the company's Miboko program, which uses the non-invasive sensor and an AI mobile application, targets the broader metabolic health and well-being space, which the non-invasive blood glucose monitoring system market is projected to reach $2 billion in 2025.

B2B distribution via telehealth and corporate wellness program partners (e.g., HealthFleet).

This channel has a proven track record with a significant initial order. The partnership with HealthFleet, a U.S.-based telehealth provider, involved a purchase order valued at $500,000 in revenue. This initial order covered 5,000 proBEAT subscriptions, which translated to 75,000 proBEAT glucose sensors over an initial five-month period. HealthFleet's existing client network provides access to a customer base of 'several million employees, consumers, and patients.'

Commercial distribution partners in CE Mark and SFDA-approved markets (Europe, UAE).

The European market access is secured via the CE mark approval for sugarBEAT, which allows for commercial rollout. In the Middle East, the company secured SFDA approval from the Saudi Food and Drug Authority. A provisional purchase order from TPMENA in that region was for 1.7 million sensors and 17,000 devices. Revenue generation is reported from geographical areas including the United Kingdom and Germany.

Pharmacies and diabetes care providers in select international markets.

Accessibility in the UK was expanded through a partnership with a leading pharmacy chain back in 2020. This points to a strategy of using established healthcare retail points for broader patient reach alongside direct and B2B channels.

Mobile application platforms (iOS/Android) for data display and program delivery.

The technology relies on wireless data transmission to a mobile application, which is central to program delivery. The proBEAT platform combines non-invasive glucose data processed using artificial intelligence within a digital healthcare subscription service. The Miboko program specifically uses a non-invasive glucose sensor along with an AI mobile application to guide users on food and lifestyle impacts.

Here's a summary of the channel activity metrics we can confirm:

Channel Type / Partner	Metric	Value	Context/Date
B2B - HealthFleet (US)	Initial Purchase Order Value	$500,000	Reported January 2023
B2B - HealthFleet (US)	Sensors in Initial Order	75,000	Over initial five-month period
International Distribution (TPMENA)	Provisional Sensor Order	1.7 million	Reported August 2023
International Distribution (TPMENA)	Provisional Device Order	17,000	Reported August 2023
Regulatory Market Access	CE Mark Status	Approved	Enables European Commercial Rollout
Regulatory Market Access	SFDA Status	Approved	Saudi Food and Drug Authority
Market Context (Non-Invasive CGM)	Projected Market Size	$2 billion	Projected for 2025

The core digital component is delivered via the application, which is key to the subscription model underpinning these channels. The company is pursuing U.S. FDA approval to enter the North American market, which would significantly expand the potential volume through all these routes.

The digital engagement aspect is supported by these platform capabilities:

• Transmits data wirelessly to a mobile application.
• Displays glucose readings at five-minute intervals for up to 24 hours.
• Provides wellness guidance notes and education via proBEAT.
• AI processing for metabolic health insights.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Segments

You're looking at Nemaura Medical Inc. (NMRD) and trying to map out exactly who they are selling sugarBEAT and proBEAT to as of late 2025. Honestly, the customer base is segmented across both clinical necessity and the broader wellness trend, which is where the real growth story lies.

Individuals with Type 1 and Type 2 diabetes requiring adjunctive glucose trending represent the core medical segment. Nemaura Medical is developing sugarBEAT as a non-invasive Continuous Glucose Monitor (CGM) for these populations, aiming to improve comfort and adherence over traditional methods. Historically, a key study showed a mix of 20 persons with Type 1 diabetes and 80 persons with Type 2 diabetes in a 100-patient cohort, indicating the larger immediate pool is Type 2. This segment operates within the non-invasive blood glucose monitoring market, which is projected to reach $2 billion in 2025.

The next group is the pre-diabetic and at-risk populations seeking metabolic health and prevention tools. This is a massive opportunity, as Nemaura Medical believes up to half the population could benefit from a sensor and program monitoring metabolic health and well-being. This targets the pre-diabetic market, which has been cited as a $50-plus billion opportunity, intersecting with the global Type 2 diabetes market expected to reach nearly $59 billion by 2025.

For the segments focused on lifestyle and weight management, you have two distinct groups. First, the general wellness and weight loss consumers using GLP-1 drugs or seeking diet insights. Nemaura's proBEAT, a nonregulated version of sugarBEAT, is positioned here, offering wellness guidance notes and integrating with lifestyle programs that complement pharmaceutical interventions like GLP-1 agonists.

Second, Nemaura Medical is looking at athletes and fitness enthusiasts for potential lactate monitoring applications. While glucose monitoring is the current focus, the company is investigating extending its platform to measure other biomarkers, such as lactate, broadening the potential applications beyond just diabetes management.

Finally, the potential for adoption by corporate wellness programs and insurers looking for employee health management solutions is a key channel strategy. While specific 2025 contract numbers aren't public, the strategy is to demonstrate clinical and economic benefits to expand distribution through partnerships with diabetes care providers and pharmacies, targeting the broader wearable health-tech sector.

Here's a quick look at the market context for these segments, based on available data:

Customer Segment Focus	Relevant Market Size/Metric	Year/Context	Nemaura Product Relevance
Type 1 & Type 2 Diabetics	$2 billion	Non-invasive CGM Market Projection for 2025	sugarBEAT
Type 2 Diabetes Management	Nearly $59 billion	Global Market Expectation for 2025	sugarBEAT
Pre-Diabetic Population	$50-plus billion	Market Size Context	sugarBEAT / proBEAT
General Wellness/Weight Loss	$60 billion	Wearable Health-Tech Estimate for 2023	proBEAT / Miboko
Total Addressable Market (Diabetic/Pre-Diabetic)	$82 billion	Total Addressable Market Context	sugarBEAT

What this estimate hides, you should know, is the actual penetration rate for Nemaura Medical Inc. (NMRD) itself; as of May 2024, the market cap was only $1.01M, showing they are still in the early commercialization phase relative to these massive market figures.

• Individuals with Type 1 and Type 2 diabetes.
• Pre-diabetic and at-risk populations.
• Wellness programs and insurers.
• GLP-1 users seeking diet insights.
• Potential lactate monitoring users.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Cost Structure

You're looking at the hard costs Nemaura Medical Inc. faces to keep the sugarBEAT platform moving from development to commercial scale. It's a mix of heavy upfront investment in science and ongoing costs for manufacturing and market access. Here's the quick math on where the money goes, based on the latest reported figures and forward-looking regulatory costs.

High Research and Development (R&D) expenses

Research and Development expenses are a significant drain, reflecting the need to refine the technology and support ongoing regulatory submissions. For the fiscal year ended March 31, 2023, Nemaura Medical Inc. reported R&D expenses of approximately $1,538,615. Management had anticipated that spending in this area would remain reasonably consistent in the fiscal year following that report.

Manufacturing costs for the disposable sugarBEAT sensors and rechargeable transmitters

The cost structure includes scaling production for both the disposable sensors and the rechargeable transmitters. Nemaura Medical Inc. outsources manufacturing, working with a partner, Nemaura Pharma, to scale up component manufacturing and final assembly in the UK. Additionally, the electronic transmitter manufacturing is supported by a contract manufacturing partner, Benchmark Electronics Inc., at their facility in Thailand, which is FDA approved.

While specific unit costs for Nemaura Medical Inc. aren't public, the operational setup involves significant commitment to contract manufacturing agreements:

Cost Component Area	Associated Partner/Location	Relevant Financial Data Point
Sensor/Transmitter Scale-up	Nemaura Pharma (UK)	Costs and timing of developing a commercial scale manufacturing facility are key variables.
Transmitter Manufacturing	Benchmark Electronics Inc. (Thailand)	Focus on facilitating future volume scale-up manufacture.
General Market Cost Proxy (Metabolite Patch)	Global Market Data (2024)	Implied Cost-of-Goods-Sold per unit of $37,500 (based on a market ASP of $50,000 per K unit and 25% gross margin)

Sales, General, and Administrative (SG&A) costs to support global commercialization efforts

Supporting commercialization, especially in the EU where CE mark approval is secured, drives up the General and Administrative portion of operating expenses. For the three months ended June 30, 2023, Nemaura Medical Inc. reported General and Administrative expenses of $1,508,467. These costs cover the infrastructure needed to support sales, distribution, and general corporate functions.

Significant regulatory compliance and clinical trial costs (e.g., FDA PMA process)

Navigating the U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) process is a major, non-recurring, but substantial cost center. Nemaura Medical Inc. submitted its PMA application in July 2020. Based on the FDA User Fees for Fiscal Year 2026 (effective October 1, 2025), the costs associated with maintaining this regulatory status or filing future submissions are concrete figures you must budget for:

• Standard FDA PMA Application Fee (FY 2026): $579,272
• Small Business Fee for PMA Application (FY 2026): $144,818
• Annual Fee for Periodic Reporting on a Class III device (PMA) (FY 2026): $20,275 (Standard) or $5,069 (Small Business)

If Nemaura Medical Inc. qualifies for the Small Business Determination (SBD) program, they may be eligible for a waiver on the first PMA application fee, but the annual reporting fees are still a recurring compliance cost.

Marketing and customer acquisition costs for the subscription-based digital programs

The digital programs, like proBEAT™, which combine glucose data with AI processing under a subscription service, involve customer acquisition costs. An initial purchase order from HealthFleet Inc. gives us a view into the value exchange for these programs. This order involved 5,000 proBEAT subscriptions, covering 75,000 glucose sensors over five months, and was valued at $500,000 in revenue.

This suggests that the cost structure must absorb the expense of the disposable sensors within the subscription price, plus the ongoing costs of maintaining the digital platform and coaching services. The total market for wellness applications using this technology was estimated to reach $60 billion by 2023, showing the scale of potential marketing spend required to capture share.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Revenue Streams

You're looking at the core ways Nemaura Medical Inc. (NMRD) brings in cash right now, late in 2025. It's a mix, as you'd expect from a MedTech firm transitioning from development to scale, heavily reliant on product sales and digital service adoption.

The most immediate, concrete financial data point for the near term is the forecast. Honestly, the quarterly revenue picture is still quite lean, reflecting the early commercialization stage. For the third quarter of 2025, the revenue forecast sits around $500K.

The primary engine for the business model is the sale of the sugarBEAT system hardware. This involves two components:

• Sales of the rechargeable transmitter.
• Sales of the disposable sensors.

Beyond the hardware, the recurring revenue component is key, tied to the digital health and coaching services. This is where the long-term value is built, assuming high patient engagement. These streams include:

• Subscription revenue from the proBEAT digital health and coaching services.
• Subscription revenue from the MiBoKo digital health and coaching services.

We also look for larger, less frequent revenue injections from strategic agreements. This covers licensing fees and milestone payments that come from commercial distribution partners as they hit certain targets or secure regional approvals. These are lumpy but important for cash flow.

To give you a snapshot of the B2B side, which can provide significant upfront revenue, you should remember the initial HealthFleet order. This was a firm commitment, valued at $500,000 in revenue, announced back in January 2023. That initial order covered 75,000 proBEAT glucose sensors over a five-month period, showing the potential volume tied to a single partner contract.

Here's a quick look at how these revenue components fit into the overall structure, based on the company's stated model:

Revenue Stream Category	Specific Component	Known Financial Data Point (2023/Forecast)
Product Sales (Hardware)	sugarBEAT System (Transmitter & Sensors)	75,000 sensors in initial HealthFleet order.
Recurring Service Revenue	proBEAT & MiBoKo Subscriptions	Forecasted quarterly revenue of $500K for Q3 2025.
Strategic/Partnership Revenue	Licensing Fees and Milestone Payments	No specific 2025 amounts publicly available.
B2B Initial Orders	HealthFleet Purchase Order	Initial order valued at $500,000.

The company generates revenue primarily from the direct sales of the sugarBEAT system, which includes the sensors and transceivers, aimed at diabetes and pre-diabetes management. Also, revenue is recognized through partnerships with distributors and healthcare providers who integrate sugarBEAT into their service offerings. The focus on digital platforms, like proBEAT, is intended to capture recurring revenue alongside the disposable sensor sales.

Finance: draft 13-week cash view by Friday.